Explore the vast range of titles available.

We present Rubin Data Preview 1 (DP1), the first data from the National Science Foundation–Department of Energy Vera C. Rubin Observatory, comprising raw and calibrated single-epoch images, coadds, difference images, detection catalogs, and ancillary data products. DP1 is based on 1792 optical–near-infrared exposures acquired over 48 distinct nights by the Rubin Commissioning Camera (LSSTComCam) on the Simonyi Survey Telescope at the Summit Facility on Cerro Pachón, Chile in late 2024. DP1 covers ∼15 deg2 distributed across seven roughly equal-sized noncontiguous fields, each independently observed in six broad photometric bands, ugrizy. The median FWHM of the point-spread function across all bands is approximately 1 .″ 14, with the sharpest images reaching about 0 .″ 58. The 5σ point-source depths for coadded images in the deepest field, the Extended Chandra Deep Field South, are u = 24.55, g = 26.18, r = 25.96, i = 25.71, z = 25.07, and y = 23.1. Other fields are no more than 2.2 mag shallower in any band, where they have nonzero coverage. DP1 contains approximately 2.3 million distinct astrophysical objects, of which 1.6 million are extended in at least one band in coadds, and 431 solar system objects, of which 93 are new discoveries. DP1 is approximately 3.5 TB in size and is available to Vera C. Rubin Observatory data rights holders via the Rubin Science Platform, a cloud-based environment for the analysis of petascale astronomical data. While small compared to future LSST releases, its high quality and diversity of data support a broad range of early science investigations ahead of full operations in 2026.

We report on the observation and measurement of astrometry, photometry, morphology, and activity of the interstellar object 3I/ATLAS, also designated C/2025 N1 (ATLAS) with the NSF-DOE Vera C. Rubin Observatory. Comet 3I/ATLAS, the third known interstellar object, was discovered on UT 2025 July 1. Rubin Observatory had coincidentally collected images of the object’s region of the sky during routine commissioning. Facilitated by Rubin’s high resolution and large aperture, we successfully recovered object detections from Rubin observations spanning UT 2025 June 21 (10 days before discovery, when 3I/ATLAS was 4.5 au from the Sun) through the date of discovery, and we acquired additional images through UT 2025 July 20 as part of commissioning. We measure on-sky locations of 3I/ATLAS in Rubin ugrizy bands, with a typical precision of ∼70 mas, and briefly describe the reason this is coarser than our measured static source astrometric precision of ∼3 mas in Rubin images. We measure grizy magnitudes of 3I/ATLAS photometry at ∼0.01 mag precision, detecting no short-term photometric variability above 0.01 mag. We derive an estimated near-nucleus dust-to-nucleus scattering cross-sectional ratio of η ≳ 13 on UT 2025 July 2 based on Rubin photometry and an upper limit nucleus size computed from Hubble Space Telescope observations. We find Rubin colors of g − r = (0.657 ± 0.013) mag, r − i = (0.235 ± 0.018) mag, i − z = (0.147 ± 0.042) mag, and z − y = (0.047 ± 0.052) mag. These data represent the earliest observations of this object by a large (≳8 m class) telescope and illustrate the type of measurements (and discoveries) Rubin’s Legacy Survey of Space and Time will provide after it begins in early 2026.

The 2010 Astronomy and Astrophysics Decadal Survey report, New Worlds, New Horizons in Astronomy and Astrophysics (NWNH), outlines a scientifically exciting and programmatically integrated plan for both ground- and space-based astronomy and astrophysics in the 2012-2021 decade. However, late in the survey process, the budgetary outlook shifted downward considerably from the guidance that NASA had provided to the decadal survey. And since August 2010-when NWNH was released-the projections of funds available for new NASA Astrophysics initiatives has decreased even further because of the recently reported delay in the launch of the James Webb Space Telescope (JWST) to no earlier than the fourth quarter of 2015 and the associated additional costs of at least $1.4 billion. These developments jeopardize the implementation of the carefully designed program of activities proposed in NWNH. In response to these circumstances, NASA has proposed that the United States consider a commitment to the European Space Agency (ESA) Euclid mission at a level of approximately 20 percent. This participation would be undertaken in addition to initiating the planning for the survey's highest-ranked, space-based, large-scale mission, the Wide-Field Infrared Survey Telescope (WFIRST). The Office of Science and Technology Policy (OSTP) requested that the National Research Council (NRC) convene a panel to consider whether NASA's Euclid proposal is consistent with achieving the priorities, goals, and recommendations, and with pursuing the science strategy, articulated in NWNH. The panel also investigated what impact such participation might have on the prospects for the timely realization of the WFIRST mission and other activities recommended by NWNH in view of the projected budgetary situation. The panel convened a workshop on November 7, 2010. The workshop presentations identified several tradeoffs among options: funding goals less likely versus more likely to be achieved in a time of restricted budgets; narrower versus broader scientific goals; and U.S.-only versus U.S.-ESA collaboration. The panel captured these tradeoffs in considering four primary options: Option A: Launch of WFIRST in the Decade 2012-2021; Option B: A Joint WFIRST/Euclid Mission; Option C: Commitment by NASA of 20 percent Investment in Euclid prior to the M-class decision; or Option D: No U.S. Financing of an Infrared Survey Mission This Decade.

We report on the observation and measurement of astrometry, photometry, morphology, and activityof the interstellar object 3I/ATLAS, also designated C/2025 N1 (ATLAS) with the NSF-DOE Vera C. Rubin Observatory. Comet 3I/ATLAS, the third known interstellar object, was discovered on UT 2025 July 1. Rubin Observatory had coincidentally collected images of the object's region of the sky during routine commissioning. Facilitated by Rubin's high resolution and large aperture, we successfully recovered object detections from Rubin observations spanning UT 2025 June 21 (10 days before discovery, when 3I/ATLAS was 4.5 au from the Sun) through the date of discovery, and we acquired additional images through UT 2025 July 20 as part of commissioning. We measure on-sky locations of 3I/ATLAS in Rubin ugrizy bands, with a typical precision of about 70 mas, and briefly describe the reason this is coarser than our measured static source astrometric precision of about 3 mas in Rubin images. We measure grizy magnitudes of 3I/ATLAS photometry at about 0.01 mag precision, detecting no short-term photometric variability above 0.01 mag. We derive an estimated near-nucleus dust-to-nucleus scattering cross-section ratio of eta >= 13 on UT 2025 July 2 based on Rubin photometry and an upper limit nucleus size computed from Hubble Space Telescope observations. We find Rubin colors of g - r = (0.657 +/- 0.013) mag, r - i = (0.235 +/- 0.018) mag, i - z = (0.147 +/- 0.042) mag, z - y = (0.047 +/- 0.052) mag. These data represent the earliest observations of this object by a large (>=8-meter class) telescope and illustrate the type of measurements (and discoveries) Rubin's Legacy Survey of Space and Time (LSST) will begin to provide after it begins in early 2026.

We present Rubin Data Preview 1 DP1, the first data from the NSF DOE Vera C Rubin Observatory, comprising raw and calibrated single epoch images, coadds, difference images, detection catalogs, and ancillary data products. DP1 is based on 1792 optical near infrared exposures acquired over 48 distinct nights by the Rubin Commissioning Camera LSSTComCam on the Simonyi Survey Telescope at the Summit Facility on Cerro Pachón Chile in late 2024. DP1 covers \\(\\)15 deg\\(^2\\) distributed across seven roughly equal-sized non-contiguous fields, each independently observed in six broad photometric bands \\(ugrizy\\). The median FWHM of the point spread function across all bands is approximately 1.14 arcseconds, with the sharpest images reaching about 0.58 arcseconds. The 5\\(\\) point source depths for coadded images in the deepest field the Extended Chandra Deep Field South are \\(u\\) = 24.55, \\(g\\) = 26.18, \\(r\\) = 25.96, \\(i\\) = 25.71, \\(z\\) = 25.07, \\(y\\) = 23.1. Other fields are no more than 2.2 magnitudes shallower in any band where they have nonzero coverage. DP1 contains approximately 2.3 million distinct astrophysical objects, of which 1.6 million are extended in at least one band in coadds and 431 solar system objects of which 93 are new discoveries. DP1 is approximately 3.5 TB in size and is available to Rubin data rights holders via the Rubin Science Platform a cloud based environment for the analysis of petascale astronomical data. While small compared to future LSST releases its high quality and diversity of data support a broad range of early science investigations ahead of full operations in 2026.

An improved understanding of etiological mechanisms in Parkinson’s disease (PD) is urgently needed because the number of affected individuals is projected to increase rapidly as populations age. We present results from a blood-based methylome-wide association study of PD involving meta-analysis of 229 K CpG probes in 1,132 cases and 999 controls from two independent cohorts. We identify two previously unreported epigenome-wide significant associations with PD, including cg06690548 on chromosome 4. We demonstrate that cg06690548 hypermethylation in PD is associated with down-regulation of the SLC7A11 gene and show this is consistent with an environmental exposure, as opposed to medications or genetic factors with effects on DNA methylation or gene expression. These findings are notable because SLC7A11 codes for a cysteine-glutamate anti-porter regulating levels of the antioxidant glutathione, and it is a known target of the environmental neurotoxin β-methylamino-L-alanine (BMAA). Our study identifies the SLC7A11 gene as a plausible biological target in PD. Parkinson’s disease (PD) is a common neurodegenerative disorder with a complex etiology involving genetics and the environment. Here, Vallerga et al. identify two CpG probes associated with PD in a blood cell type-corrected epigenome-wide meta-analysis, implicating the SLC7A11 gene as a plausible biological target.

To evaluate the associations between adiposity measures (body mass index, waist circumference, and waist-to-height ratio) with decline in glomerular filtration rate (GFR) and with all cause mortality. Individual participant data meta-analysis. Cohorts from 40 countries with data collected between 1970 and 2017. Adults in 39 general population cohorts (n=5 459 014), of which 21 (n=594 496) had data on waist circumference; six cohorts with high cardiovascular risk (n=84 417); and 18 cohorts with chronic kidney disease (n=91 607). GFR decline (estimated GFR decline ≥40%, initiation of kidney replacement therapy or estimated GFR <10 mL/min/1.73 m ) and all cause mortality. Over a mean follow-up of eight years, 246 607 (5.6%) individuals in the general population cohorts had GFR decline (18 118 (0.4%) end stage kidney disease events) and 782 329 (14.7%) died. Adjusting for age, sex, race, and current smoking, the hazard ratios for GFR decline comparing body mass indices 30, 35, and 40 with body mass index 25 were 1.18 (95% confidence interval 1.09 to 1.27), 1.69 (1.51 to 1.89), and 2.02 (1.80 to 2.27), respectively. Results were similar in all subgroups of estimated GFR. Associations weakened after adjustment for additional comorbidities, with respective hazard ratios of 1.03 (0.95 to 1.11), 1.28 (1.14 to 1.44), and 1.46 (1.28 to 1.67). The association between body mass index and death was J shaped, with the lowest risk at body mass index of 25. In the cohorts with high cardiovascular risk and chronic kidney disease (mean follow-up of six and four years, respectively), risk associations between higher body mass index and GFR decline were weaker than in the general population, and the association between body mass index and death was also J shaped, with the lowest risk between body mass index 25 and 30. In all cohort types, associations between higher waist circumference and higher waist-to-height ratio with GFR decline were similar to that of body mass index; however, increased risk of death was not associated with lower waist circumference or waist-to-height ratio, as was seen with body mass index. Elevated body mass index, waist circumference, and waist-to-height ratio are independent risk factors for GFR decline and death in individuals who have normal or reduced levels of estimated GFR.

The achievements of cell-based therapeutics have galvanized efforts to bring cell therapies to the market. To address the demands of the clinical and eventual commercial-scale production of cells, and with the increasing generation of large clinical datasets from chimeric antigen receptor T-cell immunotherapy, from transplants of engineered haematopoietic stem cells and from other promising cell therapies, an emphasis on biomanufacturing requirements becomes necessary. Robust infrastructure should address current limitations in cell harvesting, expansion, manipulation, purification, preservation and formulation, ultimately leading to successful therapy administration to patients at an acceptable cost. In this Review, we highlight case examples of cutting-edge bioprocessing technologies that improve biomanufacturing efficiency for cell therapies approaching clinical use. This Review discusses the manufacturing of cell products for clinically advanced cell therapies, and highlights potential manufacturing bottlenecks and solutions towards the cost-effective commercialization of the therapies.

BACKGROUNDGut decontamination (GD) can decrease the incidence and severity of acute graft-versus-host disease (aGVHD) in murine models of allogeneic hematopoietic cell transplantation (HCT). In this pilot study, we examined the impact of GD on gut microbiome composition and the incidence of aGVHD in HCT patients.METHODSWe randomized 20 patients undergoing allogeneic HCT to receive (GD) or not receive (no-GD) oral vancomycin-polymyxin B from day -5 through neutrophil engraftment. We evaluated shotgun metagenomic sequencing of serial stool samples to compare the composition and diversity of the gut microbiome between study arms. We assessed clinical outcomes in the 2 arms and performed strain-specific analyses of pathogens that caused bloodstream infections (BSI).RESULTSThe 2 arms did not differ in the predefined primary outcome of Shannon diversity of the gut microbiome at 2 weeks post-HCT (genus, P = 0.8; species, P = 0.44) or aGVHD incidence (P = 0.58). Immune reconstitution of T cell and B cell subsets was similar between groups. Five patients in the no-GD arm had 8 BSI episodes versus 1 episode in the GD arm (P = 0.09). The BSI-causing pathogens were traceable to the gut in 7 of 8 BSI episodes in the no-GD arm, including Staphylococcus species.CONCLUSIONWhile GD did not differentially affect Shannon diversity or clinical outcomes, our findings suggest that GD may protect against gut-derived BSI in HCT patients by decreasing the prevalence or abundance of gut pathogens.TRIAL REGISTRATIONClinicalTrials.gov NCT02641236.FUNDINGNIH, Damon Runyon Cancer Research Foundation, V Foundation, Sloan Foundation, Emerson Collective, and Stanford Maternal & Child Health Research Institute.

T cell alloreactivity against minor histocompatibility antigens (mHAgs)—polymorphic peptides resulting from donor–recipient (D–R) disparity at sites of genetic polymorphisms—is at the core of the therapeutic effect of allogeneic hematopoietic cell transplantation (allo-HCT). Despite the crucial role of mHAgs in graft-versus-leukemia (GvL) and graft-versus-host disease (GvHD) reactions, it remains challenging to consistently link patient-specific mHAg repertoires to clinical outcomes. Here we devise an analytic framework to systematically identify mHAgs, including their detection on HLA class I ligandomes and functional verification of their immunogenicity. The method relies on the integration of polymorphism detection by whole-exome sequencing of germline DNA from D–R pairs with organ-specific transcriptional- and proteome-level expression. Application of this pipeline to 220 HLA-matched allo-HCT D–R pairs demonstrated that total and organ-specific mHAg load could independently predict the occurrence of acute GvHD and chronic pulmonary GvHD, respectively, and defined promising GvL targets, confirmed in a validation cohort of 58 D–R pairs, for the prevention or treatment of post-transplant disease recurrence. The success of hematopoietic cell transplants is predicted by profiling minor histocompatibility antigens.